JP2017509649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509649A5 JP2017509649A5 JP2016558023A JP2016558023A JP2017509649A5 JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5 JP 2016558023 A JP2016558023 A JP 2016558023A JP 2016558023 A JP2016558023 A JP 2016558023A JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- dose
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955588P | 2014-03-19 | 2014-03-19 | |
| US61/955,588 | 2014-03-19 | ||
| PCT/US2015/021551 WO2015143209A1 (en) | 2014-03-19 | 2015-03-19 | Methods of treating transplant rejection using a domain antibody directed against cd40l |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509649A JP2017509649A (ja) | 2017-04-06 |
| JP2017509649A5 true JP2017509649A5 (enExample) | 2018-04-05 |
Family
ID=53055087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558023A Withdrawn JP2017509649A (ja) | 2014-03-19 | 2015-03-19 | Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170051059A1 (enExample) |
| EP (1) | EP3119809A1 (enExample) |
| JP (1) | JP2017509649A (enExample) |
| KR (1) | KR20160124912A (enExample) |
| CN (1) | CN106132429A (enExample) |
| AU (1) | AU2015231180B2 (enExample) |
| BR (1) | BR112016018813A2 (enExample) |
| CA (1) | CA2943177A1 (enExample) |
| EA (1) | EA201691634A1 (enExample) |
| IL (1) | IL247048A0 (enExample) |
| MX (1) | MX2016011102A (enExample) |
| SG (1) | SG11201606521VA (enExample) |
| WO (1) | WO2015143209A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2700651B1 (en) | 2008-07-18 | 2019-04-10 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| CN106794255A (zh) | 2014-09-30 | 2017-05-31 | 百时美施贵宝公司 | 使用针对cd28的域抗体治疗系统性红斑狼疮的方法 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| CN108473561B (zh) * | 2015-11-27 | 2022-12-16 | 埃博灵克斯股份有限公司 | 抑制cd40l的多肽 |
| WO2017160975A1 (en) | 2016-03-16 | 2017-09-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| SG10202111207TA (en) | 2017-05-24 | 2021-11-29 | Als Therapy Development Inst | Therapeutic anti-cd40 ligand antibodies |
| BR112021026410A2 (pt) * | 2019-07-01 | 2022-02-08 | Tonix Pharma Ltd | Anticorpos anti-cd154 e usos dos mesmos |
| EP4688856A1 (en) | 2023-04-03 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| JP4746552B2 (ja) * | 2003-11-04 | 2011-08-10 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用 |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| SI1868635T1 (sl) | 2005-04-06 | 2017-07-31 | Bristol-Myers Squibb Company | Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami |
| CA2634547C (en) | 2005-12-20 | 2016-10-11 | Bristol-Myers Squibb Company | Stable ctla4 formulation for subcutaneous administration |
| EP2700651B1 (en) * | 2008-07-18 | 2019-04-10 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
-
2015
- 2015-03-19 WO PCT/US2015/021551 patent/WO2015143209A1/en not_active Ceased
- 2015-03-19 SG SG11201606521VA patent/SG11201606521VA/en unknown
- 2015-03-19 JP JP2016558023A patent/JP2017509649A/ja not_active Withdrawn
- 2015-03-19 EP EP15721055.0A patent/EP3119809A1/en not_active Withdrawn
- 2015-03-19 US US15/122,455 patent/US20170051059A1/en not_active Abandoned
- 2015-03-19 KR KR1020167028617A patent/KR20160124912A/ko not_active Ceased
- 2015-03-19 MX MX2016011102A patent/MX2016011102A/es unknown
- 2015-03-19 EA EA201691634A patent/EA201691634A1/ru unknown
- 2015-03-19 CN CN201580014085.1A patent/CN106132429A/zh active Pending
- 2015-03-19 BR BR112016018813A patent/BR112016018813A2/pt not_active Application Discontinuation
- 2015-03-19 AU AU2015231180A patent/AU2015231180B2/en not_active Ceased
- 2015-03-19 CA CA2943177A patent/CA2943177A1/en not_active Abandoned
-
2016
- 2016-08-01 IL IL247048A patent/IL247048A0/en unknown
-
2020
- 2020-01-31 US US16/779,059 patent/US20200231676A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240174745A1 (en) | Antibody Constructs for CLDN18.2 and CD3 | |
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| AU2018312251B2 (en) | Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies | |
| JP7665600B2 (ja) | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 | |
| JP2018502060A5 (enExample) | ||
| JP2020515637A (ja) | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 | |
| JP6763529B2 (ja) | 抗クローディン−２モノクローナル抗体 | |
| SI2593128T1 (en) | Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures | |
| KR20220159989A (ko) | C19 c38 이중특이적 항체 | |
| KR20220019806A (ko) | 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도 | |
| WO2024197157A1 (en) | Cd19/cd38 multispecific antibodies | |
| CA3238406A1 (en) | Bispecific antibody and use thereof | |
| US20230093169A1 (en) | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof | |
| CN103417965A (zh) | 一种含有抗vegf抗体的药物组合物 | |
| CA3185332A1 (en) | Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein | |
| CA3107192C (en) | Antibody constructs for cldn18.2 and cd3 | |
| WO2025174812A1 (en) | Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use | |
| ES2860973T3 (es) | Diacuerpos monovalentes biespecíficos que pueden unirse a CD123 y CD3 y usos de estos | |
| WO2023036815A1 (en) | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering | |
| HK40078027B (zh) | 针对ror1的抗体及其用途 |